Advertisement

Journal of Neuro-Oncology

, Volume 12, Issue 2, pp 111–120 | Cite as

Measurements of CSF biochemical tumor markers in patients with meningeal carcinomatosis and brain tumors

  • Hidemitsu Nakagawa
  • Shigeki Kubo
  • Akira Murasawa
  • Shin Nakajima
  • Yoshikazu Nakajima
  • Shuichi Izumoto
  • Toru Hayakawa
Laboratory Investigation

Summary

CSF beta-glucuronidase, polyamines and carcinoembryonic antigen (CEA) were analyzed in 16 patients with meningeal carcinomatosis from solid tumor in systemic organs, 27 with benign brain lesions, 18 with primary brain tumors, 14 with metastatic brain tumors and 5 with leptomeningeal dissemination of other malignant diseases. Beta-glucuronidase levels in all cases of meningeal carcinomatosis, meningeal gliomatosis and meningeal lymphoma were higher than 100 μg/dl/hr; on the other hand, levels in all cases of benign brain lesions were below 100 μg/dl/hr. Levels of beta-glucuronidase and polyamines were not high in the cases with positive cytology after tumor resection. Polyamine levels were below 0.05 nmol/ml in all cases after resection of the metastatic brain tumor.

Cystic fluid of malignant tumors showed high levels of beta-glucuronidase and polyamines. On the other hand, the levels of polyamines in the cystic fluid of benign tumor were low, although the levels of beta-glucuronidase were high. Some cases of meningeal carcinomatosis with high levels of serum CEA did not show high levels of CSF CEA. For metastatic brain tumors, the cases with intraparenchymal tumors, especially with dural attachment showed high levels of beta-glucuronidase and CEA preoperatively, but they returned to normal after surgery. In cases of meningeal carcinomatosis treated by intrathecal chemotherapy with methotrexate (MTX) and cytosine arabinoside (Ara-C), CSF beta-glucuronidase reflected the neurological status better than the cell count decreased rapidly following chemotherapy and beta-glucuronidase was considered as a useful CSF marker in cases of meningeal carcinomatosis to monitor the course of the disease. The same situation was observed in CSF CEA and CEA was also considered as a useful marker when CEA levels in CSF are higher than those in serum.

Key words

brain tumor meningeal carcinomatosis cerebrospinal fluid biochemical tumor marker 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jaeckle KA: Assessment of tumor markers in cerebrospinal fluid. Clinics in Laboratory Medicine 5: 303–315, 1985Google Scholar
  2. 2.
    Wasserstrom WR, Schwartz MK, Fleisher M, Posner JB: Cerebrospinal fluid biochemical markers in the central nervous system tumors: a review. Ann Clinical Lab Sci 11: 239–251, 1981Google Scholar
  3. 3.
    Schold SC, Wasserstrom WR, Fleisher M, Schwartz MK, Posner JB: Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 8: 597–604, 1980Google Scholar
  4. 4.
    Shuttleworth E, Allen N: CSF -glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol 37: 684–687, 1980Google Scholar
  5. 5.
    Van Zanten AP, Twijinstra A, Van Benthem V, Hart AAM, Ongerboer de Viser BW: Cerebrospinal fluid β-glucuronidase activities in patients with central nervous system metastases. Clinica Chimica Acta 147: 127–134, 1985Google Scholar
  6. 6.
    Albright AL, Marton LJ, Lubich WP, Reigel DH: CSF polyamines in childhood. Arch Neurol 40: 237–240, 1983Google Scholar
  7. 7.
    Edwards MSB, Davis RL, Laurent JP: Tumor markers and cytologic features of cerebrospinal fluid. Cancer 56: 1773–1777, 1985Google Scholar
  8. 8.
    Marton LJ, Edwards MS, Levin VA, Lubich WP, Wilson CB: Predictive value of cerebrospinal fluid polyamines in medulloblastoma. Cancer Res 39: 993–997, 1979Google Scholar
  9. 9.
    Takaue Y, Nishioka K, Van Eys J: Evaluation of polyamine levels in cerebrospinal fluid of children with brain tumors. J Neuro-Oncol 3: 327–333, 1986Google Scholar
  10. 10.
    Moulinoux JP, Quemener V, LeCalve M, Chatel M, Darcel F: Polyamines in human brain tumors. J Neuro-Oncol 2: 153–158, 1984Google Scholar
  11. 11.
    Pierangeli E, Occhiogrosso M, Vailati G: Polyamines: Current review and their perspectives in neurosurgery. J Neurosurg Sci 26: 209–211, 1982Google Scholar
  12. 12.
    Abe K, Hori T: Determination of polyamines in human urine by high-performance liquid chromatography with fluorescence detection. Jap J Clin Chem 14: 315–320, 1985Google Scholar
  13. 13.
    Kremzner LT, Barrett RE, Terrano MJ: Polyamine metabolism in the central and peripheric nervous system. Ann NY Acad Sci 171: 735–748, 1970Google Scholar
  14. 14.
    Goldman SS, Volkow ND, Brodie J, Flamm ES: Putrescine metabolism in human brain tumors. J Neuro-Oncol 4: 23–29, 1986Google Scholar
  15. 15.
    Harik SI, Wehle SU, Sutton CH: Putrescine, a marker for malignant brain tumors. Neurology 28: 351, 1978Google Scholar
  16. 16.
    Harik SI, Sutton CH: Putrescine as a marker of malignant brain tumors. Cancer Res 39: 5010–5015, 1979Google Scholar
  17. 17.
    Marton LJ, Heby O, Wilson CB: Increased polyamine concentrations in the cerebrospinal fluid of patients with brain tumors. Int J Cancer 14: 731–735, 1974Google Scholar
  18. 18.
    Marton LJ, Heby O, Levin VA, Lubich WP, Crafts DC, Wilson CB: The relationship of polyamines in cerebrospinal fluid to the presence of central nervous system tumors. Cancer Res 36: 973–977, 1976Google Scholar
  19. 19.
    Campbell RA, Morris DR, Bartos D, Daves GD, Bartos F: Advances in polyamine research. Vol 2, Raven Press, New York, 1978Google Scholar
  20. 20.
    Allen N, Reagan E, Hill C: β-glucuronidase activities in cerebrospinal fluid. Arch Neurol 11: 144–154, 1964Google Scholar
  21. 21.
    Haidukewych D, Rodin E, Schmaltz S: Elevation of β-glucuronidase activity in medicated patients with epilepsy. Therapeutic Drug Monitoring 6: 15–19, 1984Google Scholar
  22. 22.
    Anlyan AJ, Starr A: β-glucuronidase activity of spinal and ventricular fluids in humans. Cancer 5: 578–580, 1952Google Scholar
  23. 23.
    Lehrer GM: Beta-glucuronidase in cerebro-spinal fluid of patients with diseases of the nervous system. Trans Amer Neurol Assoc 88: 244–245, 1963Google Scholar
  24. 24.
    Oda R, Hirose G, Emori T: The cerebrospinal fluid concentrations of β-glucuronidase and β-2-microglobulin in neurological disorders (in Japanese). Brain and Nerve 37: 155–160, 1985Google Scholar
  25. 25.
    Ongerboer de Visser BW, Van Zanten AP, Twijnstra A, Nooyen WJ, Hart AAM: Sensitivity and specificity of cerebrospinal fluid biochemical markers of central nervous system metastases. Prog Exp Tumor Res 29: 105–115, 1985Google Scholar
  26. 26.
    Tenhunen R, Iivanainen M, Kovanen J: Cerebrospinal fluid β-2-microglobulin in neurological disorders. Acta Neurol Scand 57: 366–373, 1978Google Scholar
  27. 27.
    Klee GG, Tallman RD, Goellner JR, Yanagihara T: Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 61: 9–13, 1986Google Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Hidemitsu Nakagawa
    • 1
  • Shigeki Kubo
  • Akira Murasawa
  • Shin Nakajima
  • Yoshikazu Nakajima
  • Shuichi Izumoto
  • Toru Hayakawa
    • 2
  1. 1.Department of NeurosurgeryThe Center for Adult DiseasesOsakaJapan
  2. 2.Department of NeurosurgeryOsaka University Medical SchoolOsakaJapan

Personalised recommendations